Among all treatments assessed, lixisenatide showed the highest point estimate of risk [OR = 4.09, 95% CI: 0.87–19.32], although it did not reach statistical significance (Figs. 2 A, 3 A, eFigure 3 A, Table 1 ).
← all excerpts
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials.
1
—
—